13 studies found for:    Lx1032
Show Display Options
Rank Status Study
1 Completed Telotristat Etiprate for Carcinoid Syndrome Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo
2 Completed An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
Condition: Carcinoid Syndrome
Intervention: Drug: 500 mg [14C]-LX1606
3 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 Part 1;   Drug: Mid-Low Dose LX1606 Part 1;   Drug: Mid-High Dose LX1606 Part 1;   Drug: High Dose LX1606 Part 1;   Drug: Part 2 LX1606 Expanded Cohort;   Drug: Placebo;   Drug: LX1606 Open Label Dose Extension;   Drug: LX1606 Open Label Extension 2;   Drug: LX1606 Open Label Extension 3
4 Completed TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo tablets
5 Recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
6 Completed An Open-Label Food Effect Study of Telotristat Etiprate
Condition: Healthy
Intervention: Drug: Telotristat etiprate
7 Completed
Has Results
A Study to Evaluate Safety and Efficacy of LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: 500 mg LX1606 QD;   Drug: 500 mg LX1606 TID;   Drug: Placebo
8 Completed A Thorough QT Study of Telotristat Etiprate
Condition: QT Interval
Interventions: Drug: Telotristat etiprate;   Drug: Placebo;   Drug: Moxifloxacin
9 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start);   Drug: Mid-low dose LX1606 - Day 15 (start);   Drug: Mid-high dose LX1606 - Day 29 (start);   Drug: High dose LX1606 - Day 43 (start);   Drug: 4-Week LX1606 Open Label Dose Extension;   Drug: 72-Week LX1606 Open Label Dose Extension
10 Active, not recruiting Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
Condition: Drug Interactions
Interventions: Drug: Telotristat etiprate;   Drug: Octreotide acetate
11 Completed A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects
Condition: Drug Interactions
Interventions: Drug: Telotristat etiprate;   Drug: Midazolam
12 Completed An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
Condition: Drug Interactions
Interventions: Drug: Fexofenadine;   Drug: Telotristat etiprate
13 Recruiting Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
Condition: Hepatic Impairment
Intervention: Drug: telotristat etiprate

Indicates status has not been verified in more than two years